AOD-9604 in Progreso — Fat Loss Peptide Research Guide
AOD-9604 research guide for Progreso. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't available on pharmacy shelves in Progreso or virtually any local market — it's a research compound available through a dedicated online market. What this means for Progreso researchers is that geography is secondary to your ability to verify analytical documentation — and those quality checks are available to every researcher. A credible AOD-9604 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide gives Progreso researchers the practical tools to evaluate AOD-9604 vendors systematically and source high-purity AOD-9604 with confidence.
AOD-9604: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Progreso comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate AOD-9604 Vendors
Before looking at individual vendors, establish a quality benchmark — so you can identify whether a supplier meets the standard. A COA for AOD-9604 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Community reputation in research forums is a valuable complement to COA verification — vendors with multi-year positive track records have built their reputation on real product performance. Bacteriostatic water is the correct reconstitution medium for AOD-9604 — it contains 0.9% benzyl alcohol that suppresses bacterial proliferation and extends reconstituted shelf life to approximately one month when stored at 2-8°C.
Order AOD-9604 — ships to Progreso
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the most serious safety risk associated with research-grade peptides — verify endotoxin testing is included in the batch-specific COA before any injectable research application. PubMed are the primary literature resources for AOD-9604 research; prioritise peer-reviewed studies with characterised source material over conference abstracts or single case observations.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
